Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an oral tablet for oral use. It prevents and treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult patients. GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Kytril, a selective 5‑HT3 receptor antagonist, is used to control nausea and vomiting arising from several medical interventions.

Chemotherapy-induced nausea and vomiting: prevents and treats nausea and vomiting caused by cytotoxic chemotherapy. Postoperative nausea and vomiting: reduces nausea and vomiting after surgical procedures. Radiation therapy-induced nausea and vomiting: alleviates nausea and vomiting associated with radiation treatment.

Granisetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Constipation - Dizziness - Fatigue - Diarrhea - Abdominal discomfort

Serious or Rare Side Effects: - QT interval prolongation - Severe allergic reactions (anaphylaxis, angioedema) - Serotonin syndrome when combined with serotonergic agents - Cardiac arrhythmias - Severe hypotension - Hepatic enzyme abnormalities

Before prescribing Kytril, clinicians should consider several safety aspects.

Assess cardiac history: evaluate risk of QT prolongation. Monitor ECG: perform baseline and periodic ECGs in at-risk patients. Review concomitant serotonergic drugs: avoid combinations that may trigger serotonin syndrome. Use caution in hepatic impairment: adjust therapy based on liver function. Consider renal function: monitor in severe renal disease. Store below 25°C: keep in the original pack, protect from moisture.

Granisetron may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other QT‑prolonging agents (e.g., quinidine, amiodarone) - Concurrent use of other 5‑HT3 antagonists - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) - Serotonergic drugs (e.g., SSRIs, MAO inhibitors) increasing serotonin syndrome risk - Anticholinergic agents that may exacerbate constipation

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine) reducing granisetron levels - Other antiemetics (e.g., metoclopramide) for additive effects - Diuretics causing electrolyte shifts that can affect cardiac repolarisation - Anesthetic agents that may influence QT interval